PRISM project

The PRISM (Psychiatric Ratings using Intermediate Stratified Markers) clinical study aims to develop a quantitative biological approach to the understanding and treatment of neuropsychiatric disorders, with a particular focus on the symptomatology of social withdrawal shared between schizophrenia and Alzheimer’s disease. In future, the project hopes to expand to include a third patient cohort of Major Depressive Disorder, thus further identifying differences and overlap in the underlying neurobiology of social withdrawal. See for more information.

The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This website reflects only the author’s views neither IMI JU nor EFPIA nor the European Commission are liable for any use that may be made of the information contained therein.